Investors may consider shifting focus to the medical sector amid rising energy prices driven by production disruptions in the Middle East. Key medical stocks currently hold Zacks Rank #1 (Strong Buy), indicating potential undervaluation and growth opportunities.
DaVita Inc. (DVA) has seen its stock rise over 70% year-to-date and is currently priced at $197, with an expected 40% earnings per share (EPS) growth this year. The company is trading at 13X forward earnings, below the industry average of 17X. Globus Medical Inc. (GMED), priced at $77, anticipates a 17% EPS growth this year, with its stock trading at 16X forward earnings, also below the industry average of 22X. Progyny Inc. (PGNY), currently at $22, targets a projected 11% EPS growth next year and is trading at a favorable 12X forward earnings against a 15X industry average.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
